Substantial cancer drugs beyond ambit of current price control mechanisms: Parliamentary panel

A parliamentary panel has urged for broader price controls on cancer drugs, noting that many remain unaffordable. The committee recommends regular market assessments, quality monitoring of generic medicines, and enhanced domestic research. Streamlining regulatory pathways and fostering public-private collaboration are crucial for improving access to novel therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsfilqK
via IFTTT